Bisphosphonate drug holiday: who, when and how long. - Test2 - elhamkhani - TriplyDB

Bisphosphonate drug holiday: who, when and how long.

Bisphosphonate drug holiday: who, when and how long.

http://www.wikidata.org/entity/Q36999714

about

A practical approach to osteoporosis management in the geriatric population Using an Electronic Decision Support Tool to Reduce Inappropriate Polypharmacy and Optimize Medicines: Rationale and Methods Effect of Long-Term Use of Bisphosphonates on Forearm Bone: Atypical Ulna Fractures in Elderly Woman with Osteoporosis.Safety & Efficacy of Cyclic Zoledronic Acid Therapy on Pediatric Secondary Osteoporosis.First Indian prospective randomized comparative study evaluating adherence and compliance of postmenopausal osteoporotic patients for daily alendronate, weekly risedronate and monthly ibandronate regimens of bisphosphonates.Current Controversies in the Management of Myeloma Bone Disease.Review: Breaking From Bisphosphonates.Osteoporosis, bone mineral density and CKD-MBD: treatment considerations.A 7-Year Longitudinal Trial of the Safety and Efficacy of a Vitamin/Mineral Enhanced Plant-Sourced Calcium Supplement.Osteonecrosis of the jaw in a patient treated with zoledronic acid and everolimus: a case report.Bisphosphonate drug holidays: we reap what we sow.The Effects of Systemic Therapy of PEGylated NELL-1 on Fracture Healing in Mice.Hip fracture trends in the United States, 2002 to 2015.

P2860

Q35223327-CE6F4CB2-12C1-4C60-8CC1-87F706EAC93B Q37037861-D2B3B6CA-FBF3-4AE8-BB08-C29076083A9D Q37198487-04E25E8E-482F-47DD-9AC5-CF0F574BD755 Q37242697-D2461EC4-269C-4D02-9B96-2062722975E0 Q37638700-529513CF-7742-47C2-8649-F7842B125F41 Q38748577-BAAA01A2-6EF1-4B91-BC25-65AEB683B326 Q38992765-CA611B7B-EDF1-4D2B-ACEF-8F3DE588C717 Q39255870-3A235362-6176-4CC7-847A-15DDC2E74C61 Q39991176-D92DA92C-702D-4859-AE28-CAA4598C1557 Q46027268-F2449B6F-C34C-43C4-8F00-4F589C452DF7 Q46648831-8BC7E6B6-28BC-4F61-8ACE-315FE4F2262C Q47205012-462C7240-41B3-4F76-8C47-2E4F760C67C4 Q47241208-9B655749-72A8-4349-AE58-38321424009D

P2860

Bisphosphonate drug holiday: who, when and how long.

http://www.wikidata.org/entity/Q36999714

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Bisphosphonate drug holiday: who, when and how long.

@en

type

label

Bisphosphonate drug holiday: who, when and how long.

@en

prefLabel

Bisphosphonate drug holiday: who, when and how long.

@en

P1433

Q36999714-C04D6039-4896-4A3D-9679-902AFDE3BDC3

P1476

Q36999714-4C0783A4-D7A7-4DE9-A7D1-455E91E7AB2A

P2093

Q36999714-A8FEA372-22B0-4D58-A324-F940E26F3931

Q36999714-C3904B95-9F38-4A46-BA1C-2A0D9676099C

P2860

Q36999714-1CEA4DBF-50EA-4A5A-950B-018E4B59D130

Q36999714-1D4AF312-FA54-4FA3-B527-F054DE19F2D3

Q36999714-2B442325-EA9D-4F45-BAA9-2B080F298B79

Q36999714-4CC224EA-ABB8-4C05-B622-4572C1858F86

Q36999714-4E93CEF2-CF5A-4C04-B33C-DB89B76D68B3

Q36999714-65D6BC7E-CFBC-4422-9705-D9474CF21883

Q36999714-6D06C51B-4796-4E24-9EDA-6858FAD7FB9E

Q36999714-89BEB13D-3D8F-4E16-BC99-53E60C4CF56A

Q36999714-A915298A-A523-4C94-95C9-D9956686ED72

Q36999714-AE224DB0-41D1-4C07-87A8-6FC8282C3B38

P304

Q36999714-F3C765E0-B32C-4C30-9DAA-1C7940FF5C2C

P31

Q36999714-161D3178-8FD1-4AF6-8C4B-4D6E11CE452D

Q36999714-445e1187-1c11-4d14-9eb5-8fdecff61d3b

P356

Q36999714-18D21991-3D8F-43F6-8190-44D51E5EAC3B

P433

Q36999714-8A9D7FA5-B825-4DBD-91B0-117F30A09DAE

P478

Q36999714-F4DFD54E-3469-4FAD-A80F-6200B8EC8EB6

P577

Q36999714-6E10278E-3ABA-4468-96A6-150DFC1D4FED

P5875

Q36999714-84827B77-368D-4C05-92FC-C40747CB0D24

P698

Q36999714-F786F0EB-A875-49DD-A67B-BC3F4A9065E2

P932

Q36999714-AA12956A-F877-43A8-873D-B60DBD50459D

P356

1759720X13477714

P1433

Therapeutic advances in musculoskeletal disease

P1476

Bisphosphonate drug holiday: who, when and how long.

@en

P2093

Dima L Diab

http://www.w3.org/2001/XMLSchema#string

Nelson B Watts

http://www.w3.org/2001/XMLSchema#string

P2860

Continuing bisphosphonate treatment for osteoporosis--for whom and for how long?

The incidence of osteonecrosis of the jaw in patients receiving 5 milligrams of zoledronic acid: data from the health outcomes and reduced incidence with zoledronic acid once yearly clinical trials program.

Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy.

Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur.

Bisphosphonates for osteoporosis--where do we go from here?

Bone safety of long-term bisphosphonate treatment.

The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT).

Long-term use of bisphosphonates in osteoporosis.

Bisphosphonates for postmenopausal osteoporosis.

Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial.

P304

107-111

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1759720X13477714

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P577

2013-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

249649127

http://www.w3.org/2001/XMLSchema#string

P698

23858334

http://www.w3.org/2001/XMLSchema#string

P932

3707342

http://www.w3.org/2001/XMLSchema#string